末梢T細胞リンパ腫(Peripheral T-Cell Lymphomas (PTCL))：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral T-Cell Lymphomas (PTCL) Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) – Overview 9
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) – Comparative Analysis 10
Peripheral T-Cell Lymphomas (PTCL) – Therapeutics under Development by Companies 11
Peripheral T-Cell Lymphomas (PTCL) – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Peripheral T-Cell Lymphomas (PTCL) – Products under Development by Companies 16
Peripheral T-Cell Lymphomas (PTCL) – Companies Involved in Therapeutics Development 18
AB Science 18
Affimed Therapeutics AG 19
Bayer AG 20
Celgene Corporation 21
Eisai Co., Ltd. 22
Incyte Corporation 23
Karyopharm Therapeutics, Inc. 24
Kyowa Hakko Kirin Co., Ltd. 25
Millennium Pharmaceuticals, Inc. 26
Mundipharma International Limited 27
Onxeo SA 28
Sanofi 29
Solasia Pharma K.K. 30
Spectrum Pharmaceuticals, Inc. 31
TG Therapeutics, Inc. 32
Peripheral T-Cell Lymphomas (PTCL) – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
AFM-13 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alemtuzumab – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
alisertib – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
belinostat – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
copanlisib – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
darinaparsin – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
denileukin diftitox – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
forodesine hydrochloride – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
lenalidomide – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
masitinib – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
mogamulizumab – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pralatrexate – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
romidepsin – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ruxolitinib phosphate – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
selinexor – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SH-7129 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
TGR-1202 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Peripheral T-Cell Lymphomas (PTCL) – Recent Pipeline Updates 90
Peripheral T-Cell Lymphomas (PTCL) – Dormant Projects 142
Peripheral T-Cell Lymphomas (PTCL) – Discontinued Products 143
Peripheral T-Cell Lymphomas (PTCL) – Product Development Milestones 144
Featured News & Press Releases 144
Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma 144
Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco 144
Nov 13, 2014: Onxeo Confirms Receipt of the $25M Milestone Payment on Beleodaq 145
Nov 06, 2014: Celgene To Present Phase II Trial Data On Romidepsin at American Society of Hematology Annual Meeting 146
Sep 16, 2014: Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq (belinostat) for Injection with Patent Term Adjustment till 2027 146
Aug 28, 2014: Onxeo Strengthens Beleodaq Patent Protection in the U.S. Until 2027 147
Jul 07, 2014: FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq (belinostat) for Injection 147
Jul 03, 2014: BioAlliance Pharma Receives FDA approval for Beleodaq 149
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 149
Feb 06, 2014: FDA Grants Acceptance To File And Priority Review For TopoTarget A/S’s Beleodaq NDA In PTCL 149
Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 152
Disclaimer 153